It has been 15 years since the advent of the genome-wide association study (GWAS) era.
Here, we review how this experimental design has realized its promise by facilitating an …

The increasing availability of biomedical data from large biobanks, electronic health records,
medical imaging, wearable and ambient biosensors, and the lower cost of genome and …

Identification of individuals at highest risk of coronary artery disease (CAD)—ideally before
onset—remains an important public health need. Prior studies have developed genome …

Parkinson's disease is a progressive neurodegenerative movement disorder with a long
latent phase and currently no disease-modifying treatments. Reliable predictive biomarkers …

Genome-wide association studies (GWAS) test hundreds of thousands of genetic variants
across many genomes to find those statistically associated with a specific trait or disease …

Polygenic risk scores (PRSs) summarize the genetic predisposition of a complex human trait
or disease and may become a valuable tool for advancing precision medicine. However …

Rare diseases affect 30 million people in the USA and more than 300–400 million
worldwide, often causing chronic illness, disability, and premature death. Traditional …

A variety of ethical concerns about artificial intelligence (AI) implementation in healthcare
have emerged as AI becomes increasingly applicable and technologically advanced. The …

A plethora of work has shown that AI systems can systematically and unfairly be biased
against certain populations in multiple scenarios. The field of medical imaging, where AI …

The use of machine learning (ML) in healthcare raises numerous ethical concerns,
especially as models can amplify existing health inequities. Here, we outline ethical …